GSK Plc has reached an agreement with BELLUS Health Inc under which it will acquire the Canadian company for $14.75 per share of common stock in cash giving a deal value of $2 billion. BELLUS is a specialty pharma company whose lead product, camlipixant, is in a Phase 3 programme for refractory chronic cough. The compound is an antagonist of P2X3, a protein which functions as a ligand-gated ion channel.
